Stocktwits on MSN
HIMS stock's rally may have plenty of room left: FDA opens door to testosterone therapy
The FDA signaled openness to expanding testosterone therapy use for low libido linked to idiopathic hypogonadism, a condition without a known cause. ・Hims began building its testosterone-care platform ...
Hypogonadal.com launches an online platform offering evidence-based medical education on low testosterone and hypogonadism. The platform states its content is reviewed by board-certified ...
RALEIGH, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Base Healthcare today announced the official launch of its subscription-based men’s virtual health platform, which focuses on foundational health and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results